# Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men

> **NCT01200862** · PHASE2 · TERMINATED · sponsor: **Mereo BioPharma** · enrollment: 29 (actual)

## Conditions studied

- Obese Hypogonadotropic Hypogonadism

## Interventions

- **DRUG:** Investigational new drug company code: BGS649
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01200862
- **Lead sponsor:** Mereo BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-08
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2020-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01200862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01200862, "Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01200862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*